Literature DB >> 27574930

Delayed Presentation of Hepatocellular Liver Injury After Nintedanib Administration.

Jacqueline L Olin1, J Andrew Woods, Stuart J Garner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27574930     DOI： 10.1097/MJT.0000000000000464

Source DB:  PubMed          Journal:  Am J Ther        ISSN： 1075-2765            Impact factor:   2.688


× No keyword cloud information.
  3 in total

Review 1.  Prevalence and current therapy in chronic liver disorders.

Authors:  Muhammad Daniyal; Muhammad Akram; Rida Zainab; Naveed Munir; Aamir Sharif; Syed Muhammad Ali Shah; Bin Liu; Wei Wang
Journal:  Inflammopharmacology       Date:  2019-02-08       Impact factor: 4.473

2.  Liver Injury with Nintedanib: A Pharmacovigilance-Pharmacokinetic Appraisal.

Authors:  Emanuel Raschi; Michele Fusaroli; Milo Gatti; Paolo Caraceni; Elisabetta Poluzzi; Fabrizio De Ponti
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-23

3.  Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study.

Authors:  Tang-Hsiu Huang; Chin-Wei Kuo; Chian-Wei Chen; Yau-Lin Tseng; Chao-Liang Wu; Sheng-Hsiang Lin
Journal:  BMC Pulm Med       Date:  2021-05-15       Impact factor: 3.317
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.